The Cryptic Gonadotropin-Releasing Hormone Neuronal System Of
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Hormonal Regulation of Oligodendrogenesis I: Effects Across the Lifespan
biomolecules Review Hormonal Regulation of Oligodendrogenesis I: Effects across the Lifespan Kimberly L. P. Long 1,*,†,‡ , Jocelyn M. Breton 1,‡,§ , Matthew K. Barraza 2 , Olga S. Perloff 3 and Daniela Kaufer 1,4,5 1 Helen Wills Neuroscience Institute, University of California, Berkeley, CA 94720, USA; [email protected] (J.M.B.); [email protected] (D.K.) 2 Department of Molecular and Cellular Biology, University of California, Berkeley, CA 94720, USA; [email protected] 3 Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143, USA; [email protected] 4 Department of Integrative Biology, University of California, Berkeley, CA 94720, USA 5 Canadian Institute for Advanced Research, Toronto, ON M5G 1M1, Canada * Correspondence: [email protected] † Current address: Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA 94143, USA. ‡ These authors contributed equally to this work. § Current address: Department of Psychiatry, Columbia University, New York, NY 10027, USA. Abstract: The brain’s capacity to respond to changing environments via hormonal signaling is critical to fine-tuned function. An emerging body of literature highlights a role for myelin plasticity as a prominent type of experience-dependent plasticity in the adult brain. Myelin plasticity is driven by oligodendrocytes (OLs) and their precursor cells (OPCs). OPC differentiation regulates the trajectory of myelin production throughout development, and importantly, OPCs maintain the ability to proliferate and generate new OLs throughout adulthood. The process of oligodendrogenesis, Citation: Long, K.L.P.; Breton, J.M.; the‘creation of new OLs, can be dramatically influenced during early development and in adulthood Barraza, M.K.; Perloff, O.S.; Kaufer, D. -
LJMU Research Online
LJMU Research Online Fergani, C, Routly, JE, Jones, DN, Pickavance, LC, Smith, RF and Dobson, H KNDy neurone activation prior to the LH surge of the ewe is disrupted by LPS http://researchonline.ljmu.ac.uk/id/eprint/8794/ Article Citation (please note it is advisable to refer to the publisher’s version if you intend to cite from this work) Fergani, C, Routly, JE, Jones, DN, Pickavance, LC, Smith, RF and Dobson, H (2017) KNDy neurone activation prior to the LH surge of the ewe is disrupted by LPS. Reproduction, 154 (3). pp. 281-292. ISSN 1470-1626 LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain. The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription. For more information please contact [email protected] http://researchonline.ljmu.ac.uk/ 1 1 KNDy neurone activation prior to the LH surge of the ewe is disrupted by LPS 2 C. Fergania, J.E. -
The Determination of Activated Neurokinin B
Examining High Salt Diet, Puberty, and Interactions of Kisspeptin, Neurokinin B, and the Vasopressin Receptor Department of Zoology and Physiology, University of Wyoming Donal Skinner Dori Pitynski Brooke Fallon Background • Early puberty in females • Copenhagen Puberty Study- 2,095 girls • In 1991, mean age: 10.88 years • In 2006, mean age: 9.86 years • Adverse effects (Aksglaede, Pediatrics, 2009) Innovation (Centers for Disease Control and Prevention, 2009) KNDy cells, GnRH, and the reproductive axis • Kisspeptin, Neurokinin B, Dynorphin • GnRH: Gonadotropin releasing hormone (preoptic area) OVERVIEW Specific Aim of Research: 1. Do NKB/Kiss neurons have vasopressin receptors in rat brains? 2. Does salt increase the expression of NKB in rat brains around the time of puberty? Vasopressin • Arcuate nucleus- site of initiation of puberty • Kisspeptin neurons have V1aR- AVPV • Could the same be occurring in arcuate? • Salt = increased release of vasopressin • Link between salt and puberty via kiss/NKB (Shinji, 2013) Methods Brain tissue • Slicing on the cryostat • 20 micron slices • Fixed to slides and labeled for neurotransmitters via immunohistochemistry Immunohistochemistry • Fluorescence, double label (Dr. Mouktahr, Suez Canal University) Primary Antibody Stain 1% Serum Primary Antibody • 48 hours Rinse: 1% PBS + NaN3 Secondary Antibody Stain • Cover-slipped with Vectashield with DAPI Secondary Antibody Results from Kisspeptin/ V1aR double label DAPI V1aR Kisspeptin Merged Neurokinin B/V1aR double label • Antibodies raised in the same -
The Significance of NK1 Receptor Ligands and Their Application In
pharmaceutics Review The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy Agnieszka Majkowska-Pilip * , Paweł Krzysztof Halik and Ewa Gniazdowska Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland * Correspondence: [email protected]; Tel.: +48-22-504-10-11 Received: 7 June 2019; Accepted: 16 August 2019; Published: 1 September 2019 Abstract: To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy. Keywords: neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging 1. Introduction Neurokinin 1 receptor (NK1R), also known as tachykinin receptor 1 (TACR1), belongs to the tachykinin receptor subfamily of G protein-coupled receptors (GPCRs), also called seven-transmembrane domain receptors (Figure1)[ 1–3]. The human NK1 receptor structure [4] is available in Protein Data Bank (6E59). -
Oxytocin Intranasal Administration Affects Neural Networks Upstream of GNRH Neurons
J Mol Neurosci (2017) 62:356–362 DOI 10.1007/s12031-017-0943-8 Oxytocin Intranasal Administration Affects Neural Networks Upstream of GNRH Neurons Mohammad Saied Salehi1 & Homayoun Khazali1 & Fariba Mahmoudi2 & Mahyar Janahmadi3 Received: 8 May 2017 /Accepted: 20 June 2017 /Published online: 29 June 2017 # Springer Science+Business Media, LLC 2017 Abstract The last decade has witnessed a surge in studies on neurokinin B was increased from the basal levels following the clinical applications of intranasal oxytocin as a method of the intervention. Furthermore, although intranasal-applied enhancing social interaction. However, the molecular and oxytocin decreased hypothalamic RFamide-related peptide- cellular mechanisms underlying its function are not 3 mRNA level, the dynorphin mRNA was not affected. completely understood. Since oxytocin is involved in the These observations are consistent with the hypothesis that regulation of hypothalamic-pituitary-gonadal axis by affect- applications of intranasal oxytocin can affect the GNRH ing the gonadotropin-releasing hormone (GNRH) system, the system. present study addressed whether intranasal application of oxytocin has a role in affecting GNRH expression in the male Keywords Intranasal-applied oxytocin . rat hypothalamus. In addition, we assessed expression of two Gonadotropin-releasing hormone . Kisspeptin . Neurokinin excitatory (kisspeptin and neurokinin B) and two inhibitory B . RFRP-3 (dynorphin and RFamide-related peptide-3) neuropeptides upstream of GNRH neurons as a possible route to relay oxy- tocin information. Here, adult male rats received 20, 40, or Introduction 80 μg oxytocin intranasally once a day for 10 consecutive days, and then, the posterior (PH) and anterior hypothalamus Over recent years, considerable effort has focused on under- (AH) dissected for evaluation of target genes. -
Understanding Peptide Binding in Class a G Protein-Coupled Receptors
Molecular Pharmacology Fast Forward. Published on July 10, 2019 as DOI: 10.1124/mol.119.115915 This article has not been copyedited and formatted. The final version may differ from this version. MOL# 115915 Understanding peptide binding in Class A G protein-coupled receptors Irina G. Tikhonova, Veronique Gigoux, Daniel Fourmy School of Pharmacy, Medical Biology Centre, Queen’s University Belfast, Belfast BT9 7BL, Northern Ireland, United Kingdom, (I.G.T.) INSERM ERL1226-Receptology and Therapeutic Targeting of Cancers, Laboratoire de Physique et Chimie des Nano-Objets, CNRS UMR5215-INSA, Université de Toulouse III, F- 31432 Toulouse, France. (V.G., D.F.) Downloaded from molpharm.aspetjournals.org Keywords: peptides, peptide GPCRs, peptide binding at ASPET Journals on September 30, 2021 1 Molecular Pharmacology Fast Forward. Published on July 10, 2019 as DOI: 10.1124/mol.119.115915 This article has not been copyedited and formatted. The final version may differ from this version. MOL# 115915 Running title page: Peptide Class A GPCRs Corresponding author: Irina G. Tikhonova School of Pharmacy, Medical Biology Centre, 97 Lisburn Road, Queen’s University Belfast, Belfast BT9 7BL, Northern Ireland, United Kingdom Email: [email protected] Tel: +44 (0)28 9097 2202 Downloaded from Number of text pages: 10 Number of figures: 3 molpharm.aspetjournals.org Number of references: 118 Number of tables: 2 Words in Abstract: 163 Words in Introduction: 503 Words in Concluding Remarks: 661 at ASPET Journals on September 30, 2021 ABBREVIATIONS: AT1, -
Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease
cells Review Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease Chongxu Zhang 1, Tengjiao Cui 1, Renzhi Cai 1, Medhi Wangpaichitr 1, Mehdi Mirsaeidi 1,2 , Andrew V. Schally 1,2,3 and Robert M. Jackson 1,2,* 1 Research Service, Miami VAHS, Miami, FL 33125, USA; [email protected] (C.Z.); [email protected] (T.C.); [email protected] (R.C.); [email protected] (M.W.); [email protected] (M.M.); [email protected] (A.V.S.) 2 Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33101, USA 3 Department of Pathology and Sylvester Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33101, USA * Correspondence: [email protected]; Tel.: +305-575-3548 or +305-632-2687 Received: 25 August 2020; Accepted: 17 October 2020; Published: 21 October 2020 Abstract: Growth hormone-releasing hormone (GHRH) is secreted primarily from the hypothalamus, but other tissues, including the lungs, produce it locally. GHRH stimulates the release and secretion of growth hormone (GH) by the pituitary and regulates the production of GH and hepatic insulin-like growth factor-1 (IGF-1). Pituitary-type GHRH-receptors (GHRH-R) are expressed in human lungs, indicating that GHRH or GH could participate in lung development, growth, and repair. GHRH-R antagonists (i.e., synthetic peptides), which we have tested in various models, exert growth-inhibitory effects in lung cancer cells in vitro and in vivo in addition to having anti-inflammatory, anti-oxidative, and pro-apoptotic effects. One antagonist of the GHRH-R used in recent studies reviewed here, MIA-602, lessens both inflammation and fibrosis in a mouse model of bleomycin lung injury. -
Somatostatin, an Inhibitor of ACTH Secretion, Decreases Cytosolic Free Calcium and Voltage-Dependent Calcium Current in a Pituitary Cell Line
The Journal of Neuroscience November 1986, &Ii): 3128-3132 Somatostatin, an Inhibitor of ACTH Secretion, Decreases Cytosolic Free Calcium and Voltage-Dependent Calcium Current in a Pituitary Cell Line Albert0 Luini,* Deborah Lewis,t Simon Guild,* Geoffrey Schofield,t and Forrest Weight? *Laboratory of Cell Biology, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, j-Laboratory of Preclinical Studies, National Institute on Alcohol Abuse and Alcoholism, Rockville, Maryland 20852, and *Experimental Therapeutics Branch, National Institute on Neurological, Communicative Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 Somatostatin is a neurohormone peptide that inhibits a variety (corticotropin releasing factor, vasointestinal peptide, isopro- of secretory responses in different cell types. We have investi- terenol, and forskolin) and to secretagogues independent of CAMP gated the effects of somatostatin on calcium current and intra- formation, such as potassium, 8-bromocyclic AMP, calcium cellular free calcium in AtT-20 cells, a pituitary tumor line in ionophores (Axelrod and Reisine, 1984) and phorbol esters which the inhibitory actions of this peptide have been well char- (Heisler, 1984). Somatostatin blocks the stimulation of secretion acterized. At concentrations similar to those that inhibit adre- by all of these agents (Axelrod and Reisine, 1984; Richardson, nocorticotropic hormone (ACTH) release, somatostatin and its 1983). A previously described mechanism of action of somato- analogs reduced the levels of intracellular free calcium (as mea- statin is the blockade of the secretagogue-evoked stimulation sured by the Quin-2 technique). Nifedipine and other blockers of CAMP synthesis (Heisler et al., 1982). We now report a novel of voltage-dependent calcium channels also reduced cytosolic effect of somatostatin; namely, the inhibition of voltage-depen- calcium levels. -
Tachykinins in Endocrine Tumors and the Carcinoid Syndrome
European Journal of Endocrinology (2008) 159 275–282 ISSN 0804-4643 CLINICAL STUDY Tachykinins in endocrine tumors and the carcinoid syndrome Janet L Cunningham1, Eva T Janson1, Smriti Agarwal1, Lars Grimelius2 and Mats Stridsberg1 Departments of 1Medical Sciences and 2Genetics and Pathology, University Hospital, SE 751 85 Uppsala, Sweden (Correspondence should be addressed to J Cunningham who is now at Section of Endocrine Oncology, Department of Medical Sciences, Lab 14, Research Department 2, Uppsala University Hospital, Uppsala University, SE 751 85 Uppsala, Sweden; Email: [email protected]) Abstract Objective: A new antibody, active against the common tachykinin (TK) C-terminal, was used to study TK expression in patients with endocrine tumors and a possible association between plasma-TK levels and symptoms of diarrhea and flush in patients with metastasizing ileocecal serotonin-producing carcinoid tumors (MSPCs). Method: TK, serotonin and chromogranin A (CgA) immunoreactivity (IR) was studied by immunohistochemistry in tissue samples from 33 midgut carcinoids and 72 other endocrine tumors. Circulating TK (P-TK) and urinary-5 hydroxyindoleacetic acid (U-5HIAA) concentrations were measured in 42 patients with MSPCs before treatment and related to symptoms in patients with the carcinoid syndrome. Circulating CgA concentrations were also measured in 39 out of the 42 patients. Results: All MSPCs displayed serotonin and strong TK expression. TK-IR was also seen in all serotonin- producing lung and appendix carcinoids. None of the other tumors examined contained TK-IR cells. Concentrations of P-TK, P-CgA, and U-5HIAA were elevated in patients experiencing daily episodes of either flush or diarrhea, when compared with patients experiencing occasional or none of these symptoms. -
Neurohormone Secretion Persists After Post-Afterdischarge Membrane Depolarization and Cytosolic Calcium Elevation in Peptidergic Neurons in Intact Nervous Tissue
The Journal of Neuroscience, October 15, 2002, 22(20):9063–9069 Neurohormone Secretion Persists after Post-Afterdischarge Membrane Depolarization and Cytosolic Calcium Elevation in Peptidergic Neurons in Intact Nervous Tissue Stephan Michel and Nancy L. Wayne Department of Physiology, David Geffin School of Medicine at University of California at Los Angeles, Los Angeles, California 90095 The purpose of this work was to test the hypothesis that an secretion or on the post-AD membrane potential (Vm ) and electrical afterdischarge (AD) causes prolonged elevation in post-AD Ca 2ϩ signal, ruling out a role for extracellular calcium 2ϩ 2ϩ cytosolic calcium levels that is associated with prolonged se- in the post-AD elevation of [Ca ]i. Both Vm and [Ca ]i re- cretion of egg-laying hormone (ELH) from peptidergic neurons turned to baseline well before ELH secretion, such that neither in intact nervous tissue of Aplysia. Using a combination of prolonged membrane depolarization nor prolonged Ca 2ϩ sig- radioimmunoassay measurement of ELH secretion, electro- naling can fully account for the extent of the persistent secre- physiological measurement of membrane potential, and optical tion of ELH. These findings suggest a unique relationship be- imaging of the concentration of intracellular free calcium ions tween membrane excitability, Ca 2ϩ signaling, and prolonged 2ϩ ([Ca ]i ), we verified that there was persistent secretion of ELH neuropeptide secretion. after the end of the AD; this was accompanied by prolonged post-AD membrane depolarization and prolonged post-AD el- Key words: action potential; Aplysia; bag cell neurons; cal- 2ϩ evation in [Ca ]i. Extracellular treatment with the calcium che- cium imaging; calcium signaling; egg-laying hormone; exocyto- lator EGTA had no effect on the pattern or magnitude of ELH sis; membrane potential; neuroendocrine; neurosecretion ϩ Dependence of exocytosis on Ca 2 influx from extracellular fluid in living tissue. -
Acceleration of Ambystoma Tigrinum Metamorphosis by Corticotropin-Releasing Hormone 1 1,2 GRAHAM C
JOURNAL OF EXPERIMENTAL ZOOLOGY 293:94–98 (2002) RAPID COMMUNICATION Acceleration of Ambystoma tigrinum Metamorphosis by Corticotropin-Releasing Hormone 1 1,2 GRAHAM C. BOORSE AND ROBERT J. DENVER * 1Department of Ecology and Evolutionary Biology,The University of Michigan, AnnArbor,Michigan48109-1048 2 Department of Molecular,Cellular and Developmental Biology,The University of Michigan, Ann Arbor,Michigan 48109-1048 ABSTRACT Previous work of others and ours has shown that corticotropin-releasing hormone (CRH) is a positive stimulus for thyroid and interrenal hormone secretion in amphibian larvae and that activation of CRH neurons may mediate environmental e¡ects on the timing of metamorphosis. These studies have investigated CRH actions in anurans (frogs and toads), whereas there is currently no information regarding the actions of CRH on metamorphosis of urodeles (salamanders and newts). We tested the hypothesis that CRH can accelerate metamorphosis of tiger salamander (Ambystoma tigrinum) larvae. We injected tiger salamander larvae with ovine CRH (oCRH; 1 mg/day; i.p.) and mon- itored e¡ects on metamorphosis by measuring the rate of gill resorption. oCRH-injected larvae com- pleted metamorphosis earlier than saline-injected larvae.There was no signi¢cant di¡erence between uninjected and saline-injected larvae. Mean time to reach 50% reduction in initial gill length was 6.9 days for oCRH-injected animals, 11.9 days for saline-injected animals, and 14.1 days for uninjected controls. At the conclusion of the experiment (day 15), all oCRH-injected animals had completed metamorphosis, whereas by day 15, only 50% of saline-injected animals and 33% of uninjected animals had metamorphosed. -
United States Patent (19) 11 Patent Number: 6,075,120 Cheronis Et Al
USOO6075120A United States Patent (19) 11 Patent Number: 6,075,120 Cheronis et al. (45) Date of Patent: Jun. 13, 2000 54 BRADYKININ ANTAGONIST Cheronis et al., “Bradykinin antagonists: Synthesis and in vitro Activity of Bissuccinimidoalkane Peptide Dimers' 75 Inventors: John C. Cheronis, Lakewood; James Recent Progress on Kinins, (1992) pp. 551-558. K. Blodgett, Broomfield; Val Smith Whalley et al., “Novel Peptide Heterodimers Withactions. At Goodfellow; Manoj Vinayak Marathe, BK2 And Either u Opioid, NK1 Or NK2 Receptors: In Vitro both of Westminster; Lyle W. Spruce, Studies, British Journal of Pharmacology, vol. 109, Suppl., Arvada; Eric T. Whalley, Golden, all 19P, Jul 1993. of Colo. Vaverk et al., Suyccinyl Bis-Bradykinins: Potent Agonists 73 Assignee: Cortech, Inc., Denver, Colo. with Exceptional Resistance to Enzymatic Degradation, Peptide: Struc. and Func., Proceedings of the 8th Amer. Pept. Symp., Pierce Chem. Co., Rockford, IL, pp. 381-384 21 Appl. No.: 08/440,338 1983. 22 Filed: May 12, 1995 Stewart et al., Bradykinin Chemistry: Agonists and Antago nist, Advances in Experimental Medicine and Biology, Ple Related U.S. Application Data num Press, NY, NY pp. 585–589 1983. 63 Continuation of application No. 08/296,185, Aug. 29, 1994, Calixto et al., “Nonpeptide Bradykinin Antagonist, Brady which is a continuation of application No. 07/974,000, Nov. kinin Antagonists: Basic and Clinical Research, Ronald 10, 1992, abandoned, which is a continuation-in-part of Burch (Ed.), Marcel Dekker Inc., NY, NY, pp. 97-129 1991. application No. 07/859,582, Mar. 27, 1992, abandoned, which is a continuation-in-part of application No.